• Medientyp: E-Artikel
  • Titel: Coagulation activation and fibrinolysis impairment are reduced in patients with anxiety and depression when medicated with serotonergic antidepressants
  • Beteiligte: Geiser, Franziska; Conrad, Rupert; Imbierowicz, Katrin; Meier, Christian; Liedtke, Reinhard; Klingmüller, Dietrich; Oldenburg, Johannes; Harbrecht, Ursula
  • Erschienen: Wiley, 2011
  • Erschienen in: Psychiatry and Clinical Neurosciences
  • Sprache: Englisch
  • DOI: 10.1111/j.1440-1819.2011.02241.x
  • ISSN: 1323-1316; 1440-1819
  • Schlagwörter: Psychiatry and Mental health ; Neurology (clinical) ; Neurology ; General Medicine ; General Neuroscience
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: <jats:p><jats:bold>Aims: </jats:bold> Anxiety disorders have been shown to be correlated with an activation of coagulation and impairment of fibrinolysis. The aim of the study was to assess whether medication with a serotonergic antidepressant, which has been associated with abnormal bleeding, may modify this effect.</jats:p><jats:p><jats:bold>Methods: </jats:bold> Thirty‐one anxiety patients, mostly with comorbid depression, and 31 healthy controls were included in the study. Group differences between anxiety patients medicated with a serotonergic antidepressant, patients without serotonergic antidepressant and controls were assessed for activated partial thromboplastin time, fibrinogen, factor VII, factor VIII, von Willebrand factor, von Willebrand ristocetin cofactor activity, prothrombin fragment 1 + 2, thrombin‐antithrombin complex, <jats:sc>d</jats:sc>‐dimer, α2‐antiplasmin, plasmin‐α2‐antiplasmin complex (PAP), tissue plasminogen activator and plasminogen activator inhibitor. Intervening variables, such as age, sex, body mass index and smoking, were accounted for.</jats:p><jats:p><jats:bold>Results: </jats:bold> We found lower coagulation measures for fibrinogen (<jats:italic>P</jats:italic> = 0.03) and plasminogen activator inhibitor (<jats:italic>P</jats:italic> = 0.01), and higher levels of PAP (<jats:italic>P</jats:italic> = 0.046) in patients with serotonergic antidepressant than in patients without serotonergic antidepressant. When controlling for smoking and body mass index, differences between the two groups were significant for PAP (<jats:italic>P</jats:italic> = 0.02), von Willebrand ristocetin cofactor activity (<jats:italic>P</jats:italic> = 0.02) and activated partial thromboplastin time (<jats:italic>P</jats:italic> = 0.046). Coagulation scores were similar in patients with serotonergic antidepressant to those of healthy controls.</jats:p><jats:p><jats:bold>Conclusions: </jats:bold> Serotonergic antidepressants may counteract a procoagulant effect of anxiety and/or depression in anxiety patients.</jats:p>
  • Zugangsstatus: Freier Zugang